Selection and Dosing of Medications for Management of Diabetes in Patients with Advanced Kidney Disease

Authors


Address correspondence to: Jeffrey S. Berns, MD, Hospital of the University of Pennsylvania, 1 Founders Pavilion, 3400 Spruce Street, Philadelphia, PA 19104, Tel.: +1-215-662-7934, Fax: +1-215-615-1688, or e-mail: bernsj@uphs.upenn.edu.

Abstract

Diabetes mellitus is a leading cause of kidney disease worldwide. A large and expanding array of treatments for diabetes is available to improve glycemic control, including newer classes of drugs, such as thiazolidinediones and incretin-based therapies. The presence of impaired kidney function with reduced glomerular filtration rate should influence choices, dosing, and monitoring of hypoglycemic agents, as some agents require a dosing adjustment in patients with kidney disease and some are entirely contraindicated. This article reviews the clinical use of insulin and other antidiabetic therapies, focusing on pharmacokinetic properties and dosing in patients with advanced kidney disease.

Ancillary